Sanofi has seen shuffle in ratings and investments recently. StockNews.com downgraded its rating to buy. Meanwhile, Blue Trust Inc. increased their stake in the company. The biotech giant intends to greatly expand its workforce at a Hyderabad site, committing $437M to the expansion. A shifting pipeline has seen
Sanofi acquiring T-cell engagers from Vir, resulting in a 25% reduction in Vir's staff.
Sanofi's profit forecast for 2024 has risen due to strength in
Dupixent and new product launches. The company confirmed a β¬1.3B investment in a new insulin plant in Germany. Legal action has been taken against Sarepta over patent infringement. The company's consumer arm is attracting bids. Additionally, it has formed a partnership with the
NAACP to advance health equity. The
Global Health Unit is making impactful investments in healthcare startups in Africa. The company is also taking leaps in AI, aiming to transform clinical trials. A joint bid for a
$20 Billion Sanofi Unit is being considered by Bain and Cinven. A partnership with OpenAI targets advanced AI-driven drug development. Lastly,
Sanofi has received EU backing for its chronic lung disease drug.
Sanofi News Analytics from Tue, 19 Sep 2023 07:00:00 GMT to Sun, 18 Aug 2024 12:04:33 GMT -
Rating 8
- Innovation 9
- Information 7
- Rumor 7